Results 21 to 30 of about 918 (92)

Managing Hypoglycaemia in Patients With Insulinoma—A Tertiary Centre Experience and Review of the Literature

Clinical Endocrinology, Volume 102, Issue 3, Page 344-354, March 2025.
ABSTRACT The management of hypoglycaemia is pivotal in the care of patients with insulinoma. Blood glucose monitoring and regulation needs careful attention pre‐ and peri‐operatively for patients undergoing surgical resection and as part of the long‐term management for patients with inoperable or metastatic disease.
Sophie Howarth, Tak‐Wai Ho, James Wimbury, Ruth Casey   +3 more
wiley   +1 more source

Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review

Journal of Endocrinological Investigation, 2018
Insulinomas are a rare type of pancreatic neuroendocrine tumours characterized by insulin hypersecretion. They are considered malignant when metastases are present. Traditional therapies often promote only temporarily symptomatic relief and may be associated with severe adverse effects.
D. Magalhães, I. L. Sampaio, G. Ferreira, P. Bogalho, D. Martins-Branco, R. Santos, H. Duarte   +6 more
openaire   +3 more sources

Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours

Journal of Neuroendocrinology, Volume 37, Issue 3, March 2025.
Abstract Peptide receptor radionuclide therapy (PRRT) using [177Lu‐DOTA0,Tyr3]octreotate (177Lu‐DOTATATE) represents an established treatment modality for somatostatin receptor‐positive, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumours (GEP NET) of grade 1 or 2.
Jelka Kuiper, Eline Zoetelief, Tessa Brabander, Wouter W. de Herder, Johannes Hofland   +4 more
wiley   +1 more source

Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors

Journal of Neuroendocrinology, Volume 37, Issue 3, March 2025.
The thera(g)nostic approach with somatostatin analog‐based agents extends beyond gastroenteropancreatic neuroendocrine tumors. Understanding tumor biological mechanisms is essential for optimizing treatment strategies. Abstract First isolated by Brazeau et al. in 1972, somatostatin (SST) is a neuropeptide known for regulating various signaling pathways
Giulia Santo, Gianpaolo di Santo, Francesco Cicone, Irene Virgolini   +3 more
wiley   +1 more source

FDA‐approved drugs featuring macrocycles or medium‐sized rings

Archiv der Pharmazie, Volume 358, Issue 1, January 2025.
This review presents 17 macrocyclic drugs approved by the U.S. Food and Drug Administration during the past 5 years, highlighting their importance and critical role in modern therapeutics, and the innovative synthetic approaches for the construction of these macrocycles.
Youlong Du, Anas Semghouli, Qian Wang, Haibo Mei, Loránd Kiss, Daniel Baecker, Vadim A. Soloshonok, Jianlin Han   +7 more
wiley   +1 more source

Elevating theranostics: The emergence and promise of radiopharmaceutical cell‐targeting heterodimers in human cancers

iRADIOLOGY, Volume 2, Issue 2, Page 128-155, April 2024.
Optimal therapeutic and diagnostic efficacy is essential for healthcare's global mission of advancing oncologic drug development. Accurate diagnosis and detection are crucial prerequisites for effective risk stratification and personalized patient care in clinical oncology.
Claudia Chambers, Broc Chitwood, Charles J. Smith, Yubin Miao   +3 more
wiley   +1 more source

Hematological Side Effects of 177Lu-DOTA-TATE Therapy in Patients with NENs

Hemato
Background/Objectives: Lutathera® ([177Lu]Lu-DOTA-TATE) is the first radiolabelled somatostatin (SST) analog approved for the treatment of patients with well-differentiated (G1 and G2) unresectable or metastatic gastro-entero-pancreatic neuro-endocrine-neoplasms (GEP-NENs).
Carideo L., Meucci R., Campagna G., Russo V. M., D'Ippolito E., Rinzivillo M., Panzuto F., Prosperi D.   +7 more
openaire   +3 more sources

Radioligand therapy (RLT) used to treat cardiac metastasis of pancreatic neuroendocrine tumor

Clinical Case Reports, Volume 12, Issue 3, March 2024.
Key Clinical Message Radioligand Therapy (RLT) in the form of [177Lu] Lu‐DOTA‐TATE (Lutathera®) is a promising treatment for pancreatic neuroendocrine tumors (pNETs) with cardiac metastasis. We present a patient treated with [177Lu] Lu‐DOTA‐TATE that showed shrinkage of metastasis after four treatments at 7.4 GBq every 8 weeks.
Kieran J. Ved, Arjun Bhatt, Aidan M. Burke, Michael C. Larkins, Dishita Pandya, Constantin B. Marcu   +5 more
wiley   +1 more source

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

International Forum of Allergy &Rhinology, Volume 14, Issue 2, Page 149-608, February 2024.
Abstract Background Sinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represent a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) aims to summarize the best available evidence and ...
Edward C. Kuan, Eric W. Wang, Nithin D. Adappa, Daniel M. Beswick, Nyall R. London Jr., Shirley Y. Su, Marilene B. Wang, Waleed M. Abuzeid, Borislav Alexiev, Jeremiah A. Alt, Paolo Antognoni, Michelle Alonso‐Basanta, Pete S. Batra, Mihir Bhayani, Diana Bell, Manuel Bernal‐Sprekelsen, Christian S. Betz, Jean‐Yves Blay, Benjamin S. Bleier, Juliana Bonilla‐Velez, Claudio Callejas, Ricardo L. Carrau, Roy R. Casiano, Paolo Castelnuovo, Rakesh K. Chandra, Vasileios Chatzinakis, Simon B. Chen, Alexander G. Chiu, Garret Choby, Naweed I. Chowdhury, Martin J. Citardi, Marc A. Cohen, Roi Dagan, Gianluca Dalfino, Iacopo Dallan, Camila Soares Dassi, John de Almeida, Angelo P. Dei Tos, John M. DelGaudio, Charles S. Ebert, Ivan H. El‐Sayed, Jean Anderson Eloy, James J. Evans, Christina H. Fang, Nyssa F. Farrell, Marco Ferrari, Nancy Fischbein, Adam Folbe, Wytske J. Fokkens, Meha G. Fox, Valerie J. Lund, Gary L. Gallia, Paul A. Gardner, Mathew Geltzeiler, Christos Georgalas, Anne E. Getz, Satish Govindaraj, Stacey T. Gray, Jessica W. Grayson, Bradley A. Gross, Jordon G. Grube, Ruifeng Guo, Patrick K. Ha, Ashleigh A. Halderman, Ehab Y. Hanna, Richard J. Harvey, Stephen C. Hernandez, Adam L. Holtzman, Claire Hopkins, Zhigang Huang, Zhenxiao Huang, Ian M. Humphreys, Peter H. Hwang, Alfred M. Iloreta, Masaru Ishii, Michael E. Ivan, Aria Jafari, David W. Kennedy, Mohemmed Khan, Adam J. Kimple, Todd T. Kingdom, Anna Knisely, Ying‐Ju Kuo, Devyani Lal, Eric D. Lamarre, Ming‐Ying Lan, Hien Le, Matt Lechner, Nancy Y. Lee, Jivianne K. Lee, Victor H. Lee, Corinna G. Levine, Jin‐Ching Lin, Derrick T. Lin, Brian C. Lobo, Tran Locke, Amber U. Luong, Kelly R. Magliocca, Svetomir N. Markovic, Gesa Matnjani, Erin L. McKean, Cem Meço, William M. Mendenhall, Loren Michel, Shorook Na'ara, Piero Nicolai, Daniel W. Nuss, Gurston G. Nyquist, Gretchen M. Oakley, Kazuhiro Omura, Richard R. Orlandi, Nobuyoshi Otori, Peter Papagiannopoulos, Zara M. Patel, David G. Pfister, Jack Phan, Alkis J. Psaltis, Mindy R. Rabinowitz, Murugappan Ramanathan Jr., Ryan Rimmer, Marc R. Rosen, Olabisi Sanusi, Zoukaa B. Sargi, Philippe Schafhausen, Rodney J. Schlosser, Ahmad R. Sedaghat, Brent A. Senior, Raj Shrivastava, Raj Sindwani, Timothy L. Smith, Kristine A. Smith, Carl H. Snyderman, C. Arturo Solares, Satyan B. Sreenath, Aldo Stamm, Katharina Stölzel, Baran Sumer, Pavol Surda, Bobby A. Tajudeen, Lester D. R. Thompson, Brian D. Thorp, Charles C. L. Tong, Raymond K. Tsang, Justin H. Turner, Mario Turri‐Zanoni, Aaron M. Udager, Thibaut van Zele, Kyle VanKoevering, Kevin C. Welch, Sarah K. Wise, Ian J. Witterick, Tae‐Bin Won, Stephanie N. Wong, Bradford A. Woodworth, Peter‐John Wormald, William C. Yao, Chien‐Fu Yeh, Bing Zhou, James N. Palmer   +158 more
wiley   +1 more source

Exploring the Potential of Nanogels: From Drug Carriers to Radiopharmaceutical Agents

Advanced Healthcare Materials, Volume 13, Issue 1, January 4, 2024.
Nanogels are universally applicable materials mainly being used for drug delivery systems, tissue engineering, and sensor development. More recently, radiolabeled nanogels have also been reported. This class of compounds holds an enormous potential for theranostic applications.
Manja Kubeil, Yota Suzuki, Maria Antonietta Casulli, Rozy Kamal, Takeshi Hashimoto, Michael Bachmann, Takashi Hayashita, Holger Stephan   +7 more
wiley   +1 more source